Formoterol/glycopyrrolate inhalation - Glenmark Pharmaceuticals

Drug Profile

Formoterol/glycopyrrolate inhalation - Glenmark Pharmaceuticals

Alternative Names: Glycopyrronium/formoterol fumarate

Latest Information Update: 08 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Antiasthmatics; Antispasmodics; Bronchodilators; Ethanolamines; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease

Most Recent Events

  • 28 Feb 2017 Phase-III clinical trials in Chronic obstructive pulmonary disease in India (Inhalation) (CTRI2017-02-007814)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top